A decade of FDA-approved drugs (2010–2019): trends and future directions
A total of 378 novel drugs and 27 biosimilars approved by the US Food and Drug
Administration (FDA) between 2010 and 2019 were evaluated according to approval …
Administration (FDA) between 2010 and 2019 were evaluated according to approval …
Recent updates on mechanisms of resistance to 5-fluorouracil and reversal strategies in colon cancer treatment
S Azwar, HF Seow, M Abdullah, M Faisal Jabar… - Biology, 2021 - mdpi.com
Simple Summary Acquired resistance to chemotherapy by cancer cells is the predominant
factor in chemotherapy failure, which ultimately leads to disease progression and death …
factor in chemotherapy failure, which ultimately leads to disease progression and death …
New horizons in lung cancer management through ATR/CHK1 pathway modulation
Lung cancer is the leading cause of cancer-related deaths worldwide. Molecular profiling
has contributed to a new classification of lung cancer, driving advancements in research and …
has contributed to a new classification of lung cancer, driving advancements in research and …
The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage–inducing or repair–compromising therapies in preclinical …
AM Wengner, G Siemeister, U Lücking, J Lefranc… - Molecular cancer …, 2020 - AACR
The DNA damage response (DDR) secures the integrity of the genome of eukaryotic cells.
DDR deficiencies can promote tumorigenesis but concurrently may increase dependence …
DDR deficiencies can promote tumorigenesis but concurrently may increase dependence …
[HTML][HTML] Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication
SARS-CoV-2 has currently precipitated the COVID-19 global health crisis. We developed a
medium-throughput drug-screening system and identified a small-molecule library of 34 of …
medium-throughput drug-screening system and identified a small-molecule library of 34 of …
Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer
R Lozano, E Castro, IM Aragón, Y Cendón… - British journal of …, 2021 - nature.com
Over the past years, several studies have demonstrated that defects in DNA damage
response and repair (DDR) genes are present in a significant proportion of patients with …
response and repair (DDR) genes are present in a significant proportion of patients with …
DNA damage response and immune defense
C Nastasi, L Mannarino, M D'Incalci - International journal of molecular …, 2020 - mdpi.com
DNA damage is the cause of numerous human pathologies including cancer, premature
aging, and chronic inflammatory conditions. The DNA damage response (DDR), in turn …
aging, and chronic inflammatory conditions. The DNA damage response (DDR), in turn …
PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA
EN Risdon, CH Chau, DK Price, O Sartor… - The oncologist, 2021 - academic.oup.com
Abstract The US Food and Drug Administration recently approved two poly‐adenosine
diphosphate‐ribose polymerase (PARP) inhibitors, olaparib and rucaparib, for treatment of …
diphosphate‐ribose polymerase (PARP) inhibitors, olaparib and rucaparib, for treatment of …
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
PA Konstantinopoulos, AABA da Costa… - Nature …, 2021 - nature.com
In a trial of patients with high grade serous ovarian cancer (HGSOC), addition of the ATR
inhibitor berzosertib to gemcitabine improved progression free survival (PFS) compared to …
inhibitor berzosertib to gemcitabine improved progression free survival (PFS) compared to …
RP-3500: a novel, potent, and selective ATR inhibitor that is effective in preclinical models as a monotherapy and in combination with PARP inhibitors
A Roulston, M Zimmermann, R Papp, A Skeldon… - Molecular cancer …, 2022 - AACR
Ataxia telangiectasia and Rad3-related (ATR) kinase protects genome integrity during DNA
replication. RP-3500 is a novel, orally bioavailable clinical-stage ATR kinase inhibitor …
replication. RP-3500 is a novel, orally bioavailable clinical-stage ATR kinase inhibitor …